alexa EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Surgery

Surgery

Journal of Trauma & Treatment

Author(s): Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA,

Abstract Share this page

Abstract PURPOSE: To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin. PATIENTS AND METHODS: This multicenter, open-label, phase III study randomly assigned 1,298 patients with epidermal growth factor receptor-expressing mCRC who had experienced first-line fluoropyrimidine and oxaliplatin treatment failure to cetuximab (400 mg/m(2) day 1 followed by 250 mg/m(2) weekly) plus irinotecan (350 mg/m(2) every 3 weeks) or irinotecan alone. Primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), response rate (RR), and quality of life (QOL). RESULTS: Median OS was comparable between treatments: 10.7 months (95\% CI, 9.6 to 11.3) with cetuximab/irinotecan and 10.0 months (95\% CI, 9.1 to 11.3) with irinotecan alone (hazard ratio [HR], 0.975; 95\% CI, 0.854 to 1.114; P = .71). This lack of difference may have been due to post-trial therapy: 46.9\% of patients assigned to irinotecan eventually received cetuximab (87.2\% of those who did, received it with irinotecan). Cetuximab added to irinotecan significantly improved PFS (median, 4.0 v 2.6 months; HR, 0.692; 95\% CI, 0.617 to 0.776; P
  • DOI: 10.1200/JCO.2007.13.1193
  • This article was published in J Clin Oncol and referenced in Journal of Trauma & Treatment

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Relevant Topics

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    Agri & Aquaculture Journals

    Dr. Krish

    [email protected]

    1-702-714-7001Extn: 9040

    Biochemistry Journals

    Datta A

    [email protected]

    1-702-714-7001Extn: 9037

    Business & Management Journals

    Ronald

    [email protected]

    1-702-714-7001Extn: 9042

    Chemistry Journals

    Gabriel Shaw

    [email protected]

    1-702-714-7001Extn: 9040

    Clinical Journals

    Datta A

    [email protected]

    1-702-714-7001Extn: 9037

    Engineering Journals

    James Franklin

    [email protected]

    1-702-714-7001Extn: 9042

    Food & Nutrition Journals

    Katie Wilson

    [email protected]

    1-702-714-7001Extn: 9042

    General Science

    Andrea Jason

    [email protected]

    1-702-714-7001Extn: 9043

    Genetics & Molecular Biology Journals

    Anna Melissa

    [email protected]

    1-702-714-7001Extn: 9006

    Immunology & Microbiology Journals

    David Gorantl

    [email protected]

    1-702-714-7001Extn: 9014

    Materials Science Journals

    Rachle Green

    [email protected]

    1-702-714-7001Extn: 9039

    Nursing & Health Care Journals

    Stephanie Skinner

    [email protected]

    1-702-714-7001Extn: 9039

    Medical Journals

    Nimmi Anna

    [email protected]

    1-702-714-7001Extn: 9038

    Neuroscience & Psychology Journals

    Nathan T

    [email protected]

    1-702-714-7001Extn: 9041

    Pharmaceutical Sciences Journals

    Ann Jose

    [email protected]

    1-702-714-7001Extn: 9007

    Social & Political Science Journals

    Steve Harry

    [email protected]

    1-702-714-7001Extn: 9042

     
    © 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords